Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers

Trial Profile

Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs Iodixanol pegol (Primary)
  • Indications Cancer; Cardiovascular disorders
  • Focus Diagnostic use
  • Sponsors Marval Pharma
  • Most Recent Events

    • 09 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top